Immunome Inc. (IMNM): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMNM Stock Price Chart Interactive Chart >
IMNM Price/Volume Stats
|Current price||$5.29||52-week high||$9.40|
|Prev. close||$5.13||52-week low||$2.09|
|Day high||$5.33||Avg. volume||193,306|
|50-day MA||$3.99||Dividend yield||N/A|
|200-day MA||$4.13||Market Cap||64.15M|
Immunome Inc. (IMNM) Company Bio
Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.
Most Popular Stories View All
IMNM Latest News Stream
|Loading, please wait...|
IMNM Latest Social Stream
View Full IMNM Social Stream
Latest IMNM News From Around the Web
Below are the latest news stories about IMMUNOME INC that investors may wish to consider to help them evaluate IMNM as an investment opportunity.
Immunome Inc. (NASDAQ:IMNM) concluded the trading at $4.72 on Friday, January 06 with a rise of 0.21% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $4.71 and 5Y monthly beta was reading 0.54 with its price kept floating in the range … Immunome Inc. (IMNM): Major Improvements, Worth A Look Read More »
Immunome and AbbVie announced a worldwide collaboration and option agreement to discover up to 10 new antibody-target pairs for treating three specific types of tumors using Immunome''s technology.
AbbVie Inc (NYSE: ABBV ) and Immunome Inc (NASDAQ: IMNM ) announced a worldwide collaboration and option agreement to discover up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome''s Discovery Engine. Immunome will receive an upfront payment of $30 million. It … Full story available on Benzinga.com
AbbVie (ABBV) has signed a collaboration agreement with Immunome (IMNM) to discover up to 10 novel antibody-target pairs for cancer treatments.
AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery
IMNM Price Returns